Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: A 120 months prospective study

Endocrine Journal

Volumn 54, Issue 5, 2007, Pages 713-720

  Cappelli, Carlo ^a   Gandossi, Elena ^a   Castellano, Maurizio ^a   Pizzocaro, Claudio ^b   Agosti, Barbara ^a   Delbarba, Andrea ^a   Pirola, Ilenia ^a   De Martino, Elvira ^a   Rosei, Enrico Agabiti ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Spedali Civili of Brescia ^*  (Italy)

Author keywords

Graves' disease; Hyperthyroidism; Prognosis; Thyroid antibodies

Indexed keywords

THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; ANTITHYROID AGENT; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PROGNOSIS; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; REMISSION; TREATMENT WITHDRAWAL;

ADULT; ANTITHYROID AGENTS; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; MALE; METHIMAZOLE; MIDDLE AGED; PROGNOSIS; RECEPTORS, THYROTROPIN; RECURRENCE; REMISSION INDUCTION; WITHHOLDING TREATMENT;

EID: 40649108591     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-069     Document Type: Article

References (44)

1. Mckenna TJ (2001) Graves' disease. Lancet 357: 1793-1796.
2. Okamoto T, Iihara M, Obara T (2000) Management of hyperthyroidism due to Graves' and nodular disease. World J Surg 24: 957-961.
3. Feldt-Rasmussen U, Glinoer D, Orgiazzi J (1993). Reassessment of antithyroid drug therapy of Graves' disease. Annu Rev Med 44: 323-334.
4. Weetman AP (2000) Graves' Disease. N Engl J Med 343: 1236-1248.
5. Toft AD, Weetman AP (1998) Screening for agranulocytosis in patients treated with antithyroid drugs. Clin Endocrinol (Oxf) 49: 271-282.
6. nd generation assay for anti-TSH receptor antibodies to differentiated relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease. Endocrine J 52: 493-497.
7. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS (2005). A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 153: 489-498.
8. Levy EG (1997) Treatment of Graves' disease: The American Way. Baillieres Clin Endocrinol Metab 11: 585-595.
9. Vitti P, Rago T, Chiovato L, Pallini S, Santini F (1997) Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7: 369-375.
10. Feldt-Rasmussen U, Schleusner H, Carayon P (1994) Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long-term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 78: 98-102.
11. Michelangeli V, Poon C (1998) The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 8: 119-124.
12. Schleusener H, Schwander J, Fischer C, . (1989) Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 120: 689-701.
13. Maugendre D, Massart C (2001) Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug trated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) 54: 89-96.
14. Davies TF, Roti E, Braverman LE, De Groot LJ (1998) Thyroid controversy-stimulating antibodies. J Clin Endocrinol Metab 83: 3777-3785.
15. Zweig MH, Campbell G (1993) Receiver-operating characteristic ROC plots: a fundamental evaluation tool in clinical medicine. Clin Chem 337: 1675-1681.
16. Hershman JM, Givens JR, Cassidy CE, Astwood EB (1966) Long-term outcome of hyperthyroidism treated with antithyroid drugs. J Clin Endocrinol Metab 26: 803-807.
17. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Del ambre C, Derennes V (1990) Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatement duration. J Clin Endocrinol Metab 70: 675-679.
18. Leech NJ, Dyan CM (1998) Controversies in the management of Graves' disease. Clin Endocrinol (Oxf) 49: 273-280.
19. Orgiazzi J, Madec AM (2002) Reduction of the risk of relapse after withdrawal of medical theraphy for Graves' disease. Thyroid 12: 849-853.
20. Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E (2006) Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease bifore, at the end of methimazole treatement, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16: 295-302.
21. Massart C, Orgiazzi J, Maugendre D (2001) Clinical validity of new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs. Clin Chim Acta 304: 39-47.
22. nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical theraphy of Graves' disease. Eur J Endocrinol 146: 173-177.
23. Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seiissler J (2004) Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res 36: 92-96.
24. Nordyke RA, Gilbert FI, Harada ASM (1988) Graves' disease. Influence of age on clinical findings. Arch Intern Med 148: 623-631.
25. Aizawa T, Ishihiara M, Hashizume K, Takasu N, Yamada T (1989) Age-related changes of thyroid function and immunologic abnormalities in patients with hyperthyroidism due to Graves' disease. J Am Geriatr Soc 37: 944-948.
26. Benhaim Rochester D, Davies TF (2005) Increased risk of Graves' disease after pregnancy. Thyroid 15: 1287-1290.
27. Allahabadia A, Daykyn J, Holder RL (2000) Age and gender predict the outcome of teatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 85: 1038-1042.
28. Weetman AP, Ratanachaiyavong S, Middleton GW (1986) Prediction of outcome in Graves' disease after carbimazole treatment. Q J Med 228: 409-419.
29. Martino E, Pinchera A, Capiferri E (1988) Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism. J Clin Endocrinol Metab 3: 543-549.
30. Clague R, Mukhtar ED, Pyle GA, et al. (1976) Thyroid stimulating immunoglobulins on the control of thyroid function. J Clin Endocrol Metab 43: 50-56.
31. Michico U, Satoshi I, Hideo S (2002) Thyroid specific T helper cell analysis by ELISPOT assay with thyrotropin receptor peptides. Peptides 23: 103-107.
32. Al-Humaidi MA (2000) Serum cytokines levels in Graves' disease. Saudi Med J 21: 639-644.
33. Bolanos F, Gonzalez-Ortiz M, Duron H, Sanchez C (2002) Remission of Graves' hyperthyroidism treated with methimazole. Rev Invest Clin 54: 307-310.
34. Bojarska-Szmygin A, Janicki K, Pietura R, Janicka L (2003) The usefulness of thyroid size and TSH receptor antibody (TRAb) determinations in predicting the effectiveness of tiamazole and I-131 treatment for Graves-Basedow's disease. Ann Univ Mariae Curie Sklodowska [Med] 58: 242-247.
35. Mevgendre D, Gate A, Campion L (1999) Antithyroid drugs and Graves' disease-prospective randomized assessment of long-term treatment. Clin Endocrinol 50: 127-132.
36. Yamada T, Aizawa T (1994) Age-related therapeutic response to antithyroi drug in patients with hyperthyroid Graves' disease. J Am Geriatr Soc 42: 513-516.
37. Cappelli C, Braga M, De Martino E, Castellano M, Gandossi E, Agosti B, Cumetti D, Pirola I, Mattanza C, Cherubini L, Agabiti Rosei E (2006) Outcome of patients surgically treated for various forms of hyperthyroidism with differentiated thyroid cancer: experience at an endocrine center in Italy. Surg Today 36: 125-130.
38. Vaiana R, Cappelli C, Perini P, Pinelli D, Camoni G, Farfaglia R, Balzano R, Braga M (1999) Hyperthyroidism and concurrent thyroid cancer. Tumori 85: 247-252.
39. Tajiri J, Noguchi S, Morita M, Tamaru M, Murakami N, Kato R (1991) Serum free triiodothyronine to free thyroxine ratio enables early prediction of the outcome of antithyroid drug theraphy in patients with Graves' hyperthyroidism. Endocrinol Jpn 38: 683-687.
40. Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, Pellegrino D (1999) Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years. J Pediatr Endocrinol Metab 12: 537-541.
41. Akamizu T (2001) Antithyrotropin receptor antibody: an update. Thyroid 11: 1123-1134.
42. Paschke R, Ludgate M (1997) The thyrotropin receptor in thyroid diseases. N Engl J Med 337: 1675-1681.
43. Saiki Y, Ishihara T, Ikekubo K, Mori T (2005) Differences in TSH receptor binding and thyroid-stimulating properties between TSH and Graves' IgG. Slowly-acting TSH receptor antibody moieties in Graves' sera affect assay data. Endocr J 52: 45-55.
44. Okamoto Y, Tanigawa SI, Ishikawa K, Hamada N (2006) TSH receptor antybody measurement and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J 53: 467-472.